Corrigendum: Safety of Semaglutide

Guardado en:

Detalles Bibliográficos
Autores principales:	Mark M. Smits, Daniël H. Van Raalte
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	glucagon-like peptide-1 receptor agonist (GLP-1RA) oral subcutaneous semaglutide type 2 diabetes safety Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/1d6095bb78274de5a98922ae3f3ed6df
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d6095bb78274de5a98922ae3f3ed6df
record_format	dspace
spelling	oai:doaj.org-article:1d6095bb78274de5a98922ae3f3ed6df2021-11-10T15:21:04ZCorrigendum: Safety of Semaglutide1664-239210.3389/fendo.2021.786732https://doaj.org/article/1d6095bb78274de5a98922ae3f3ed6df2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.786732/fullhttps://doaj.org/toc/1664-2392Mark M. SmitsDaniël H. Van RaalteFrontiers Media S.A.articleglucagon-like peptide-1 receptor agonist (GLP-1RA)oralsubcutaneoussemaglutidetype 2 diabetessafetyDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glucagon-like peptide-1 receptor agonist (GLP-1RA) oral subcutaneous semaglutide type 2 diabetes safety Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	glucagon-like peptide-1 receptor agonist (GLP-1RA) oral subcutaneous semaglutide type 2 diabetes safety Diseases of the endocrine glands. Clinical endocrinology RC648-665 Mark M. Smits Daniël H. Van Raalte Corrigendum: Safety of Semaglutide
format	article
author	Mark M. Smits Daniël H. Van Raalte
author_facet	Mark M. Smits Daniël H. Van Raalte
author_sort	Mark M. Smits
title	Corrigendum: Safety of Semaglutide
title_short	Corrigendum: Safety of Semaglutide
title_full	Corrigendum: Safety of Semaglutide
title_fullStr	Corrigendum: Safety of Semaglutide
title_full_unstemmed	Corrigendum: Safety of Semaglutide
title_sort	corrigendum: safety of semaglutide
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1d6095bb78274de5a98922ae3f3ed6df
work_keys_str_mv	AT markmsmits corrigendumsafetyofsemaglutide AT danielhvanraalte corrigendumsafetyofsemaglutide
_version_	1718439848449146880

Corrigendum: Safety of Semaglutide

Ejemplares similares